6. Treatment Options and Individualized Care

To understand the treatment options available and be able to discuss them appropriately to provide individualised patient care


Full content only available after log-in


6.1.  Knows the different treatment modalities for IBD taking into account disease extent, activity, previous history and complications

6.2.  Knows the modes of delivery of different drug therapies and their advantages and disadvantages

6.3.  Recognises the importance of patient choice in deciding therapy and in helping to ensure adherence

6.4.  Understands the evidence base behind different therapeutic strategies and when they might be appropriate (conventional step care, optimised step up, top down and treat to target)

6.5.  Appreciates the monitoring requirements for specific therapies

6.6.  Appreciates common side effects and complications of therapy, their frequency and how to manage them

6.7.  Appreciates the importance of on-going disease monitoring to confirm efficacy

6.8.  Understands when surgery is the most appropriate therapeutic option

6.9.  Is up to date with the evidence base from current clinical trial and real world data sets for the use of available therapies

6.10.  Has knowledge of the role of optimising therapy including interpretation of therapeutic drug monitoring for conventional and biological therapies

6.11.  Appreciates the role of stopping medical therapies in IBD and the appropriate timing / patient population in whom drugs can be stopped


        
 
Topic:











Programme Phase:



Content Format:








Topic 6 : Introduction

Management of IBD

J Lindsay

IBD Blue Book

Webcast
 


Topic 6 : State of the art

Management of Patients on Thiopurines

A Lopéz-Sanromán, E Domenèch

Talking Heads
 


Topic 6 : State of the art

Therapeutic Drug Monitoring

M Ferrante, A Armuzzi, F Magro

Talking Heads
 


Topic 6 : State of the art

Methotrexate Why, When, How?

A Lopéz-Sanromán, D Laharie, G Savoye

Talking Heads
 


Topic 6 : State of the art

Manipulating the microbiota in everyday practice

A Hart

ECCO 2016 Amsterdam Congress

Webcast
 


Topic 6 : State of the art

Personalised medicine: Dream or reality?

I Dotan

ECCO 2017 Barcelona Congress

Webcast + PPT
 


Topic 6 : Educational update

Treatment of dysplasia (Tandem talk)

V Annese, A Spinelli

ECCO 2016 Amsterdam Congress

Webcast
 


Topic 6 : Educational update

The role of pathology in the evaluation of treatment

V Villanacci

ECCO 2016 Amsterdam Congress

Webcast
 


Topic 6 : Educational update

Treat to target in paediatric IBD – same as in adults?

P van Rheenen

ECCO 2017 Barcelona Congress

Webcast + PPT
 


Topic 6 : Educational update

Vedolizumab in children and other biologics after TNF – what can we extrapolate? A case-based discussion

H Escher

ECCO 2017 Barcelona Congress

Webcast + PPT